Compare Ginkgo Bioworks Holdings Inc (DNA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Neurocrine Biosciences Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M), while Neurocrine Biosciences Inc trades at $151.32 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 32.5× Ginkgo Bioworks Holdings Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | NBIX | |
|---|---|---|
Market Cap | $505.73M | $16.46B |
Sector | Health | Health |
52-Week High | $16.14 | $185.50 |
52-Week Low | $5.48 | $123.10 |
Enterprise Value | $607.68M | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
